Back to top
more

THERAVANCE INC (THRX)

(Delayed Data from NSDQ)

$9.81 USD

9.81
665,485

+0.04 (0.41%)

Updated Jan 8, 2016 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?

by Zacks Equity Research

Theseus Pharmaceuticals (THRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan

by Zacks Equity Research

Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.

Down -65.65% in 4 Weeks, Here's Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss

by Zacks Equity Research

Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.

New Strong Buy Stocks for July 19th

by Zacks Equity Research

SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.

After Plunging -69.57% in 4 Weeks, Here's Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study

by Zacks Equity Research

Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.

Wall Street Analysts See a 128.83% Upside in Theseus Pharmaceuticals, Inc. (THRX): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 128.8% in Theseus Pharmaceuticals, Inc. (THRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals

by Zacks Equity Research

CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals are part of the Zacks Industry Outlook article.

4 Biotech Stocks to Consider for Your Portfolio in 2023

by Zacks Equity Research

New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.

What Makes Theseus Pharmaceuticals, Inc. (THRX) a New Buy Stock

by Zacks Equity Research

Theseus Pharmaceuticals, Inc. (THRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).